Whilst we did not see increased risk of re‐hospitalization with HF in people with reduced ACEi/ARB or beta‐blocker dose, the observed 1 year risk exceeded 10%, serving as a reminder of the scope for escalation of GDMT to improve this, especially in the ARNI and SGLT2 inhibitor era.25 Here, SLC5A2 is linked to hydrops fetalis.